Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up
Author: Morais, EO
Resende, MR
Oliveira, AM
Sinkoc, VM
Garcia, MT
Angerami, RN
Da Silva, LJ
Abstract: Background: Patients undergoing dialysis usually have a poor response to conventional hepatitis B vaccination. Aim: To observe the effects of intradermal hepatitis B (HB) vaccination in a 13-month prospective study of adult patients with end-stage renal failure. The patients were with or without previous hepatitis B vaccination, but all had antibody titres < 10 mUI/mL. Methods: Patients were allotted to two groups: previous hepatitis B virus vaccination and no previous hepatitis B virus vaccination or anti-HBs titres < 10 mUI/mL. Patients in both groups received 16 i.d. injections of 0.1 mL of hepatitis B virus vaccine over an eight-week period. Patients had antibody titres assessed before vaccination, 1 month after and every 3 months for a year. Antibody titres >= 10 mUI/mL were considered protective. Results: Seventy patients completed the protocol. Protective titres were elicited in 82% of each group. Age, time under dialysis, diabetes, smoking and body-mass index were not associated with seroconversion. Persistent protective titres > 12 months occurred in 27 (58.7%). Adverse events were trivial. Conclusion: Intradermal hepatitis B virus vaccination is an alternative in end-stage renal failure.
Country: Inglaterra
Editor: Blackwell Publishing
Citation: Alimentary Pharmacology & Therapeutics. Blackwell Publishing, v. 25, n. 7, n. 849, n. 855, 2007.
Rights: fechado
Identifier DOI: 10.1111/j.1365-2036.2007.03262.x
Date Issue: 2007
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000244976500012.pdf460.2 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.